BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther 2019;50:269-77. [PMID: 31115919 DOI: 10.1111/apt.15323] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Yokoyama Y, Ohta Y, Ogasawara S, Kato J, Arai R, Koseki H, Saito M, Kaneko T, Tokunaga M, Oura H, Oike T, Imai Y, Kanayama K, Akizue N, Kumagai J, Taida T, Okimoto K, Saito K, Ooka Y, Matsumura T, Nakagawa T, Arai M, Katsuno T, Fukuda Y, Kitsukawa Y, Kato N. The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort. Sci Rep 2022;12:21060. [PMID: 36473879 DOI: 10.1038/s41598-022-25218-x] [Reference Citation Analysis]
2 Patil SA, Bhat S, Limdi JK, Farraye FA, Cross RK. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022;28:1915-23. [PMID: 35353189 DOI: 10.1093/ibd/izac048] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jourdain H, Hoisnard L, Sbidian E, Zureik M. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System. Sci Rep 2022;12:19569. [PMID: 36380105 DOI: 10.1038/s41598-022-24050-7] [Reference Citation Analysis]
4 Kumar P, Vuyyuru SK, Kante B, Kedia S, Sahu P, Ranjan MK, Mundhra S, Golla R, Kumar M, Virmani S, Gupta A, Yadav N, Makharia G, Ahuja V. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis. Indian J Gastroenterol 2022;41:446-55. [PMID: 36378484 DOI: 10.1007/s12664-022-01252-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Overbeek JA, Kuiper JG, Bakker M, van den Bemt BJFB, Herings RMC. Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time. Br J Clin Pharmacol 2021. [PMID: 34571570 DOI: 10.1111/bcp.15097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther 2021;54:234-48. [PMID: 34114667 DOI: 10.1111/apt.16445] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
7 Bhat S, Limdi JK, Cross RK, Farraye FA. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease. Dig Dis Sci 2021;66:2513-32. [PMID: 34176024 DOI: 10.1007/s10620-021-07114-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Smith JT, Velayos FS, Niu F, Liu V, Delate T, Pola S, Le K, Hui RL. Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab051] [Reference Citation Analysis]
9 Meyer A, Semenzato L, Zureik M, Weill A, Carbonnel F, Dray-Spira R. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. Aliment Pharmacol Ther 2021;54:160-6. [PMID: 34110040 DOI: 10.1111/apt.16410] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
10 Schreiber S, Yamamoto K, Muniz R, Iwura T. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. Pharmacol Res Perspect 2020;8:e00604. [PMID: 32500668 DOI: 10.1002/prp2.604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 Buchner AM, Schneider Y, Lichtenstein GR. Biosimilars in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:45-56. [PMID: 33110013 DOI: 10.14309/ajg.0000000000000844] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Armuzzi A, Bouhnik Y, Cummings F, Bettey M, Pieper B, Kang T. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Dig Liver Dis 2020;52:1259-65. [PMID: 32601035 DOI: 10.1016/j.dld.2020.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
14 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
15 Kumari A, Prasad DN, Kumar S, Singh RK. Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor. Journal of Exploratory Research in Pharmacology 2020;000:1-9. [DOI: 10.14218/jerp.2020.00004] [Reference Citation Analysis]
16 Barré A, Dermine S, Palmieri L, Lavolé J, Malamut G, Chaussade S, Coriat R, Abitbol V. Les nouveaux traitements des maladies inflammatoires chroniques de l’intestin. La Presse Médicale Formation 2020;1:25-32. [DOI: 10.1016/j.lpmfor.2020.03.011] [Reference Citation Analysis]
17 Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther 2019;50:269-77. [PMID: 31115919 DOI: 10.1111/apt.15323] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]